Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

Journal of Diabetes and Metabolic Disorders

Volumn 14, Issue 1, 2015, Pages

  Sharma, Alok ^a   Paliwal, Geetanjali ^a   Upadhyay, Nisha ^a   Tiwari, Archana ^a  

^a Rajiv Gandhi Proudyogiki Vishwavidyalaya   (India)

Author keywords

DPP 4; DPP 4 inhibitors; GIP; GLP 1; Type 2 diabetes

Indexed keywords

RETRACTED ARTICLE; REVIEW;

EID: 85017143895     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/s40200-015-0143-4     Document Type: Review

References (94)

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clinical Investigation. 1999;104(6):787-94.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
3. Elrick H, Stimmler L, Hlad Jr C, Arai Y. Plasma Insulin Response to Oral and Intravenous Glucose Administration 1. J Clin Endocrinol Metab. 1964;24(10):1076-82.
4. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ Br Med J. 1998;317(7160):703.
5. Vilsbøll T, Holst J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47(3):357-66.
6. Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull. 2004;51(4):364-70.
7. Nauck M, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-4.
8. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126-31.
9. Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagonlike peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220-4.
10. Mentlein R. Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9-24.
11. Ahrén B. Inhibition of dipeptidyl peptidase-4 (DPP-4)-a novel approach to treat type 2 diabetes. Curr Enzym Inhib. 2005;1(1):65-73.
12. Šedo A, Vlašicová K, Barták P, Vespalec R, Vicar J, Šimánek V, et al. Quaternary benzo [c] phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV. Phytother Res. 2002;16(1):84-7.
13. Bopp A, De Bona K, Bellé L, Moresco R, Moretto M. Syzygium cumini inhibits adenosine deaminase activity and reduces glucose levels in hyperglycemic patients. Fundam Clin Pharmacol. 2009;23(4):501-7.
14. Yogisha S, Ravisha K. Dipeptidyl Peptidase IV inhibitory activity of Mangifera indica. J Nat Prod. 2010;3:76-9.
15. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929-40.
16. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. 1983.
17. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535-9.
18. Fehmann H-C, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995;16(3):390-410.
19. Gault V, O'Harte F, Harriott P, Mooney M, Green B, Flatt P. Effects of the novel (Pro3) GIP antagonist and exendin (9-39) amide on GIP-and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003;46(2):222-30.
20. Rocca A, Brubaker P. Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion 1. Endocrinology. 1999;140(4):1687-94.
21. Anini Y, Hansotia T, Brubaker PL. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology. 2002;143(6):2420-6.
22. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide 1. J Clin Endocrinol Metab. 2000;85(10):3575-81.
23. Kieffer TJ, McIntosh C, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585-96.
24. Mentlein R, GALLWITZ B, SCHMIDT WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-35.
25. Gault V, Parker J, Harriott P, Flatt P, O'Harte F. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP (3-42), is a GIP receptor antagonist in vivo. J Endocrinol. 2002;175(2):525-33.
26. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol. 1996;318(2):429-35.
27. Deacon CF, Plamboeck A, Møller S, Holst JJ. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab. 2002;282(4):E873-9.
28. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36) NH2, GLP-1-(7-37), and GLP-1-(9-36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab. 2003;88(4):1772-9.
29. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-13.
30. Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G, et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism. 2004;53(5):624-31.
31. Gautier J, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31(3):233-42.
32. Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Hörsch D. Glucosedependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001;15(9):1559-70.
33. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and antiapoptotic signaling by glucose-dependent insulinotropic polypeptide in beta (INS-1)-cells. J Endocrinol. 2002;174(2):233-46.
34. 1-42 action in vitro. Regul Pept. 1997;69(3):151-4.
35. Baggio L, Kieffer T, Drucker D. GLP-1 but not GIP regulates fasting and non-enteral glucose clearance in mice. Endocrinology. 2000;141:3703-9.
36. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci. 1999;96(26):14843-7.
37. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8(7):738-42.
38. Usdin T, Wolfe MM. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. 1996.
39. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50(5):1004-11.
40. O'Harte F, Mooney M, Kelly C, Flatt P. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol. 2000;165(3):639-48.
41. O'Harte F, Gault V, Parker J, Harriott P, Mooney M, Bailey C, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002;45(9):1281-91.
42. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994;51(1):63-74.
43. Tatarkiewicz K, Hargrove DM, Jodka CM, Gedulin BR, Smith PA, Hoyt JA, et al. A novel long acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Diab Obes Metab. 2014;16(1):75-85.
44. Knop FK, Lund A, Madsbad S, Holst JJ, Krarup T, Vilsbøll T. Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. BMC Res Notes. 2014;7(1):326.
45. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in firstdegree relatives of patients with type 2 diabetes. Diabetes. 2001;50(11):2497-504.
46. Rehfeld JF. Gastrointestinal Hormones and Their Targets. Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. New York: Springer; 2014. p. 157-75.
47. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665-73.
48. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223-6.
49. van Bloemendaal L, ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1-16.
50. Shah M, Vella A. Effects of GLP-1 on appetite and weight. Reviews in Endocrine and Metabolic Disorders. 2014:1-7. doi:10.1007/s11154-014-9289-5.
51. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci. 2000;20(4):1616-21.
52. Zheng H, Stornetta R, Agassandian K, Rinaman L. Glutamatergic phenotype of glucagon-like peptide 1 neurons in the caudal nucleus of the solitary tract in rats. Brain Struct Funct. 2014:1-12. doi:10.1007/s00429-014-0841-6.
53. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22(23):10470-6.
54. Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, et al. The Role of β Cell Glucagon-like Peptide-1 Signaling in Glucose Regulation and Response to Diabetes Drugs. Cell Metabolism. 2014. http://dx.doi.org/10.1016/j. cmet.2014.04.005.
55. Dachicourt N, Serradas P, Bailbe D, Kergoat M, Doare L, Portha B. Glucagonlike peptide-1 (7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies. J Endocrinol. 1997;155(2):369-76.
56. Wang X. Study of the Proliferation, Function and Death of Insulin-Producing Beta-Cells in vitro: Role of the Transcription Factor ZBED6. 2014.
57. Miao X-Y, Gu Z-Y, Liu P, Hu Y, Li L, Gong Y-P, et al. The human glucagonlike peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides. 2013;39:71-9.
58. Bruin JE, Rezania A, Xu J, Narayan K, Fox JK, O'Neil JJ, et al. Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia. 2013;56(9):1987-98.
59. Suen PM, Li K, Chan JC, Leung PS. In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice. Int J Biochem Cell Biol. 2006;38(5):951-60.
60. Hill DJ. Development of the endocrine pancreas. Rev Endocr Metab Disord. 2005;6(3):229-38.
61. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther. 2006;8(3):385-96.
62. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141(12):4600-5.
63. Wang Q, Brubaker P. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002;45(9):1263-73.
64. Edvell A, Lindström P. Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå+/?) 1. Endocrinology. 1999;140(2):778-83.
65. Boland CL, DeGeeter M, Nuzum DS, Tzefos M. Diabetes; Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors. Ann Pharmacother. 2013;47(4):490-505.
66. Gao Z, Bai G, Chen J, Zhang Q, Pan P, Bai F, et al. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci Biotechnol Biochem. 2009;73(3):688-94.
67. Li L, El-Kholy W, Rhodes C, Brubaker P. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005;48(7):1339-49.
68. Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011;54(5):1098-108.
69. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Investig. 1998;101(7):1421.
70. Edwards C, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999;48(1):86-93.
71. Scrocchi LA, Hill ME, Saleh J, Perkins B, Drucker DJ. Elimination of glucagonlike peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes. 2000;49(9):1552-60.
72. Gagnon J, Baggio LL, Drucker DJ, Brubaker PL. Ghrelin is a Novel Regulator of Glucagon-like Peptide-1 Secretion. Diabetes. 2014:DB_141176. [Epub ahead of print].
73. Ling Z, Wu D, Zambre Y, Flamez D, Drucker D, Pipeleers DG, et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 2001;438(4):382-7.
74. De León DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes. 2003;52(2):365-71.
75. De Meester I, Lambeir A-M, Proost P, Scharpé S. Dipeptidyl peptidase IV substrates. Dipeptidyl Aminopeptidases in Health and Disease. US: Springer; 2003 p. 3-17.
76. Kieffer TJ, Francis HJ. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913.
77. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952-7.
78. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med. 2006;57:265-81.
79. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth H-U. Investigation of Glucose-dependent Insulinotropic Polypeptide (1-42) and Glucagon-like Peptide-1-(7-36) Degradation in Vitro by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry A novel kinetic approach. J Biol Chem. 1996;271(38):23222-9.
80. Holmes D. Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 Diabetes. Horm Metab Res. 2006;38:423-8.
81. Mest H-J, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48(4):616-20.
82. Mardanyan S, Sharoyan S, Antonyan A, Zarkanyan IV N. Dipeptidyl peptidase IV and adenosine deaminase inhibition by Armenian plants and antidiabetic drugs. Int J Diab Metab. 2011;19:69-74.
83. Ceriello A, Sportiello L, Rafaniello C, Rossi F. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf. 2014;13(S1):57-68.
84. Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, et al. Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2014;57(8):3205-12.
85. Hach T, Ferrannini E. 5. The future of anti-diabetics in T2DM therapy. The significance of the kidney in diabetes. 2012:81.
86. Piteau S, Olver A, Kim S-J, Winter K, Pospisilik JA, Lynn F, et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun. 2007;362(4):1007-12.
87. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57.
88. Kanazawa I, Tanaka K-i, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit. 2014;20:1662.
89. de Heer J, Göke B. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas? Expert Opin Drug Saf. 2014;13(11):1469-81.
90. Hu G, Rico-Sanz J, Lakka T, Tuomilehto J. Exercise, genetics and prevention of type 2 diabetes. Essays Biochem. 2006;42:177-92.
91. Lans CA. Journal of Ethnobiology and Ethnomedicine. J Ethnobiol Ethnomed. 2006;2:45.
92. Chakrabarti R, Bhavtaran S, Narendra P, Varghese N. Dipeptidyl peptidase-IV inhibitory activity of Berberis aristata. Journal of Natural Products. 2011;4:158-63.
93. Geng Y, Lu Z-M, Huang W, Xu H-Y, Shi J-S, Xu Z-H. Bioassay-guided isolation of DPP-4 inhibitory fractions from extracts of submerged cultured of Inonotus obliquus. Molecules. 2013;18(1):1150-61.
94. Singh AK, Jatwa R, Joshi J. Cytoprotective and dipeptidyl peptidase IV (Dpp-Iv/Cd26) inhibitory roles of ocimum sanctum and momordica charantia extract. Asian J Pharm Clin Res. 2014;7:1.